Huabin Zhu

Dr. Huabin Zhu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
JQJane Qin
Jane Qin
JJJu Hyeong Jeon
Ju Hyeong Jeon
JXJiangsheng Xu
Jiangsheng Xu
LLLaura Katherine Langston
Laura Katherine Langston
RMRamesh Marasini
Ramesh Marasini
HZHuabin Zhu
Huabin Zhu
Because of the rapid mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an effective vaccine against SARS-CoV-2 variants is needed to prevent coronavirus disease 2019 (COVID-19). T cells, in addition to neutralizing antibodies, are an important component of naturally acquired protective immunity, and a number of studies have shown that T cells induced by natural infection or vaccination contribute significantly to protection against several viral infections including SARS-CoV-2. However, it has never been tested whether a T cell-inducing vaccine can provide significant protection against SARS-CoV-2 infection in the absence of preexisting antibodies. In this study, we designed and evaluated lipid nanoparticle (LNP) formulated mRNA vaccines that induce only T cell responses or both T cell and neutralizing antibody responses by using two mRNAs. One mRNA encodes SARS-CoV-2 Omicron Spike protein in prefusion conformation for induction of neutralizing antibodies. The other mRNA encodes over one hundred T cell epitopes (multi-T cell epitope or MTE) derived from non-Spike but conserved regions of the SARS-CoV-2. We show immunization with MTE mRNA alone protected mice from lethal challenge with the SARS-CoV-2 Delta variant or a mouse-adapted virus MA30. Immunization with both mRNAs induced the best protection with the lowest viral titer in the lung. These results demonstrate that induction of T cell responses, in the absence of preexisting antibodies, is sufficient to confer protection against severe disease, and that a vaccine containing mRNAs encoding both the Spike and MTE could be further developed as a universal SARS-CoV-2 vaccine.

7 March 2025 in Cancers
Verified
Journal Article
Open access
SLSarrah Lahorewala
Sarrah Lahorewala
CPChandramukhi S. Panda
Chandramukhi S. Panda
KAKarina Aguilar
Karina Aguilar
DMDaley Morera
Daley Morera
HZHuabin Zhu
Huabin Zhu
VLVinata B Lokeshwar
Vinata B Lokeshwar
Among the 152,810 estimated new cases of adenocarcinoma of the colon (COAD) and the rectum (READ) in 2024, the rates of colorectal cancer (CRC) are increasing in young adults (age < 55 years)